Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RE 104

Next Previous
Drug Profile

RE 104

Alternative Names: RE-104

Latest Information Update: 23 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Reunion Neuroscience
  • Class Antidepressants; Small molecules
  • Mechanism of Action Serotonin 5-HT2A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Adjustment disorders; Postnatal depression

Most Recent Events

  • 16 Sep 2025 Reunion Neuroscience plans a phase III trial for Postnatal depression in 2026
  • 16 Sep 2025 Reunion Neuroscience plans the phase II RECLAIM trial for Generalised anxiety disorder in first quarter of 2026
  • 19 Aug 2025 Reunion Neuroscience initiates enrolment in a phase-I trial (In volunteers) in USA (SC) (NCT07146191)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top